Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

24d ago, source: Business Insider

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered ...

OncoCyte Corp (OCX) Q4 2023 Earnings Call Transcript Highlights: Strategic Partnerships and ...

23d ago, source: Yahoo Finance

Average Burn Rate: Reduced to $3.91 million over the past three quarters from $11 million in the same period a year ago. Partnership Investment: Bio-Rad invested in a $15.8 million private ...

Q4 2023 OncoCyte Corp Earnings Call

23d ago, source: Yahoo Finance

Jeff Ramson; Investor Relations; PCG Advisory Inc. Joshua Riggs; President, Chief Executive Officer, Director; OncoCyte Corp Mike Matson; Analyst; Needham & Company ...

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

23d ago, source: Seeking Alpha

My name is JL, and I will be your conference operator today. At this time, I would like to welcome everyone to the OncoCyte Fourth Quarter and Year-end 2023 Earnings Conference Call. [Operator ...

Oncocyte Reports Full Year 2023 Financial Results

24d ago, source: Business Insider

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.

OncoCyte Corp OCX

13d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Bio-Rad announces collaboration agreement with oncocyte to commercialize transplant monitoring with droplet digital PCR

20d ago, source: Hosted on MSN

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation ...

OncoCyte Corp (OCX) Q4 2023 Earnings Call Transcript Highlights: Strategic Partnerships and ...

23d ago, source: Yahoo Finance

Q4 Non-GAAP Operating Loss: $4.2 million, an increase of $1.2 million compared to the same period in 2022. OncoCyte Corp has successfully reduced its average burn rate from $11 million to $3.91 ...